Michael Pehl and Lauren Wood

Michael Pehl has been the President and CEO of Immunomedics (NASDAQ: IMMU) since December 2017 and has more than two decades of experience in hematology and oncology. Previously, he served as President, Hematology & Oncology, at Celgene Corporation, and prior to that was the company’s Head of Global Marketing, Head of Hematology Europe and the first General Manager of Celgene in Germany. Over the course of his 11 years at Celgene, Michael has launched multiple blockbuster drugs in the areas of hematology and oncology, including Revlimid, Pomalyst, and Abraxane.

Michael has demonstrated an exceptional acumen for realizing lifecycle opportunities and developing pipeline drugs, reflected by the steep revenue growth of Celgene’s Hematology and Oncology business. Under his leadership, Celgene developed and launched the Acute Myeloid Leukemia (AML) drug IDHIFA in industry-record time, and also built an industry-leading pipeline of late and early stage products to treat multiple high-unmet need conditions. Prior to his time as Celgene, Michael served in a number of commercial leadership positions at Amgen in Europe.

Lauren Wood is Head of Patient Experience and Corporate Communications at Immunomedics. She works across the patient ecosystem to understand the daily impacts of cancer on our lives in order to develop solutions, product innovations, and partnerships that make a meaningful impact. Working with healthcare executives, internal stakeholders, and partners across the country, she is focused on elevating the company's profile as a valuable partner to people living with cancer and their healthcare providers. Prior to joining Immunomedics, she was the Director of Strategy and Development for the Healthcare Practice at the storied design and innovation firm, frog. Lauren holds an MBA from Brown University and a BBA from The University of Victoria.

Posts by Michael Pehl and Lauren Wood